Regentis Biomaterials (RGNT) Stock Analysis

What Regentis Biomaterials does

Regentis Biomaterials Ltd. is a regenerative medicine firm dedicated to crafting innovative solutions for tissue repair, ultimately aiming to enhance patients' health and overall quality of life. The company's primary product in development is GelrinC, a novel, cell-free, ready-to-use hydrogel designed to be solidified into an implant within the knee. This implant serves to address painful knee injuries and mend articular cartilage damage. Regentis Biomaterials leverages its proprietary Gelrin platform, which employs biodegradable hydrogel implants, to develop orthopedic therapies that facilitate the regeneration of compromised or diseased tissues. The company was established in 2004 and operates from its headquarters in Herzliya, Israel.

Key metrics

ETFs linked to RGNT

Broad-market and Healthcare sector ETFs an investor holding Regentis Biomaterials is often also exposed to. Open an ETF page to see its actual top holdings.

PortView Portfolio Insights

PortView analyzes how RGNT fits your actual portfolio — position weight, portfolio concentration, unrealized gain/loss, contribution to return, sector exposure, indirect exposure through the ETFs you hold, and correlation with your other holdings. Connect a portfolio to see your personalized figures; PortView never shows another user's private holdings.

Similar companies

Frequently asked questions

What is the ticker symbol for Regentis Biomaterials?

Regentis Biomaterials trades under the ticker RGNT on AMEX.

Which exchange is RGNT listed on?

RGNT is listed on AMEX.

What sector does Regentis Biomaterials operate in?

Regentis Biomaterials is classified in the Healthcare sector (Medical - Instruments & Supplies industry).

How can PortView help analyze RGNT in a portfolio?

PortView shows RGNT's weight in your portfolio, its contribution to return and risk, sector exposure, indirect exposure through ETFs you own, and correlation with your other holdings.